SPI Pharma launches flash ODT platform

UltraBurst is suitable for products from prescription drugs to nutraceuticals

SPI Pharma has introduced UltraBurst, an excipient platform for flash ODTs that reportedly enabled disintegration in under ten seconds.

The platform is designed for direct compression and can deliver its disintegration of any preformulated product on the market while maintaining hardness, friability, API loading, and assorted tablet weights, SPI claims.

“Across a wide range of different API loadings and tablet sizes, we can demonstrate significant reduction in disintegration time against the current market alternatives. We see reductions in disintegration times between 20-40% without loss of tablet hardness or increased friability,” said John McInerney, General Manager of the Excipients and Drug Delivery Systems Business Unit.

The platform is suitable for products from prescription drugs to nutraceuticals.

McInerney continued, “We are excited about the opportunities that UltraBurst presents to our customers. Not only does UltraBurst make flash ODT dose forms more widely available to formulators, it does so in a package that’s easy to use and delivers on low manufacturing costs.”

Orally disintegrating tablets are suitable for anyone with difficulty swallowing, improving compliance in these cases.

Companies